Yi Fang Wang

US Patent:

7353554, Apr 8, 2008

Filed:

Aug 1, 2006

Appl. No.:

11/496785

Inventors:

Yi Jing Wang - Rowland Heights CA, US

International Classification:

A47C 27/08

US Classification:

5665, 5422, 5669, 5413 R

Abstract:

The floating water bed includes a specially designed unique sleeping bag and a movable mattress pad. The sleeping bag is both thin and soft and it is placed on top of the movable mattress pad. This movable mattress pad can be lowered or risen from the water. As the human being rests within the sleeping bag, with the press of a button, the mattress pad can be lowered into the water along with the sleeping bag and the individual inside. At this time, the individual inside the sleeping bag will be floating in mid-water and will begin experiencing soothing relaxation. The floating water bed will have a well-shaped hole perpendicular to the sleeping bag and rising out of the water, providing the individual with an entrance into the sleeping bag as well as a breathing space once they are within the sleeping bag. With this well-shaped hole, the individual can breathe easily without the use of oxygen masks or additional equipment. This new floating water bed can then truly produce the effects of reducing stress, increasing bodily strength, improving sleep, and relieving muscular fatigue.

US Patent:

7614104, Nov 10, 2009

Filed:

Dec 14, 2007

Appl. No.:

12/002123

Inventors:

Yi Jing Wang - Rowland Heights CA, US
Zhirong Wang - Rowland Heights CA, US

International Classification:

A47C 27/08

US Classification:

5665, 5422, 5669, 5413 R

Abstract:

A floating water bed for a user being floatably surrounded with liquid, includes a sleeping bed, which is made of waterproof material, having a compartment for the user accommodating therein that the user is floating and supporting by the liquid, and a breathing opening communicating with the compartment and arranged in such a manner that when the user rests in the compartment, the breathing opening is aligned with a head of the user, wherein the breathing opening is adapted for air circulation of the compartment with ambient atmosphere, such that the sleeping bag is adapted for allowing the user to achieve absolute relaxation while achieving complete rest, wherein the sleeping bag is adapted for completely separating the user from the liquid surrounding and thus protecting the user within the sleeping bag.

US Patent:

20230026872, Jan 26, 2023

Filed:

Mar 22, 2018

Appl. No.:

16/494556

Inventors:

- San Diego CA, US
Linda V. KESSLER - San Diego CA, US
Liansheng LI - San Diego CA, US
Pingda REN - San Diego CA, US
Yi WANG - San Diego CA, US
Tao WU - San Diego CA, US
Jingchuan ZHANG, I - San Diego CA, US

International Classification:

A61K 31/519
A61P 35/02
A61K 31/454
A61K 31/4725
A61K 31/453
A61K 31/5377
A61K 31/445
A61K 31/44
A61K 31/505
A61K 31/4523
A61K 31/4545

Abstract:

The present disclosure provides methods for treating hematological malignancies and Ewings sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

US Patent:

20210317127, Oct 14, 2021

Filed:

Aug 1, 2019

Appl. No.:

17/264744

Inventors:

- San Diego CA, US
Jun FENG - San Diego CA, US
Tao WU - Carlsbad CA, US
Yuan LIU - San Diego CA, US
Yi WANG - San Diego CA, US
Alana K. BORUM - Encinitas CA, US
Pingda REN - San Diego CA, US
Yi LIU - San Diego CA, US

International Classification:

C07D 487/10
C07D 519/00

Abstract:

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, L, L, L, A, A, A, A, G, G, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

US Patent:

20210221332, Jul 22, 2021

Filed:

Jun 20, 2019

Appl. No.:

17/255998

Inventors:

- San Diego CA, US
Ruiliang ZHANG - San Diego CA, US
Xiaoling HAN - San Diego CA, US
Lindong SUN - San Diego CA, US
Liu LIU - San Diego CA, US
Yi WANG - San Diego CA, US

International Classification:

B60R 25/30
B60R 25/33
B60R 25/32
B60R 25/102
G06F 21/55
G06F 21/57
G06F 21/60
H04W 12/108
H04W 12/106
H04L 9/32
H04W 4/40
H04W 4/80
H04W 4/90

Abstract:

Disclosed are devices, systems and methods for securing wireless communications between a remote monitor center and a vehicle by using redundancy measures to increase the robustness of the system. In some embodiments, a system may include redundant communication channels, deploy redundant hardware and software stacks to enable switching to a backup in an emergency situation, and employ hypervisors at both the remote monitor center and the vehicle to monitor hardware and software resources and perform integrity checks. In other embodiments, message digests based on a cryptographic hash function and a plurality of predetermined commands are generated at both the remote monitor center and the vehicle, and compared to ensure the continuing integrity of the wireless communication system.

US Patent:

20210107917, Apr 15, 2021

Filed:

Jul 13, 2020

Appl. No.:

16/927844

Inventors:

- San Diego CA, US
- Ann Arbor MI, US
Yi WANG - San Diego CA, US
Pingda REN - San Diego CA, US
Jolanta GREMBECKA - Ann Arbor MI, US
Tomasz CIERPICKI - Ann Arbor MI, US
Szymon KLOSSOWSKI - Ann Arbor MI, US
Jonathan POLLOCK - Ann Arbor MI, US
Dmitry BORKIN - Ann Arbor MI, US

International Classification:

C07D 495/04
A61K 31/445
A61P 35/02

Abstract:

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

US Patent:

20210101908, Apr 8, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/944040

Inventors:

- San Diego CA, US
- Ann Arbor MI, US
Yi WANG - San Diego CA, US
Pingda REN - San Diego CA, US
Jolanta GREMBECKA - Ann Arbor MI, US
Tomasz CIERPICKI - Ann Arbor MI, US
Szymon KLOSSOWSKI - Ann Arbor MI, US
Jonathan POLLOCK - Ann Arbor MI, US
Dmitry BORKIN - Ann Arbor MI, US

International Classification:

C07D 495/04
A61P 35/00

Abstract:

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

US Patent:

20210024501, Jan 28, 2021

Filed:

Jun 29, 2020

Appl. No.:

16/915942

Inventors:

- San Diego CA, US
Jun Feng - San Diego CA, US
Tao Wu - Carlsbad CA, US
Yuan Liu - San Diego CA, US
Yi Wang - San Diego CA, US
Pingda Ren - San Diego CA, US
Yi Liu - San Diego CA, US

International Classification:

C07D 403/14
C07D 401/14
C07D 413/14
A61P 35/00
C07D 417/14
C07D 403/04
C07D 405/14
C07D 471/04
C07D 487/08

Abstract:

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, R, R, R, R, R, R, R, R, L, L, L, E, m, mand * are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Author:

Yi Wang

ISBN #:

7802170354